China Biotech’s new crown vaccine unblind for another two months to build the world’s largest vaccine production workshop
On June 28, Sinopharm China National Biotech announced that the blind review and staged unblinding meeting of the phase I/II clinical trial of the new coronavirus inactivated vaccine developed by the Beijing Institute of Biological Products was held, initially indicating the safety of the new coronavirus vaccine developed this time. effective.
“Double insurance” research and development of new crown vaccine unblind results are safe and effective
According to the information released by China Biotechnology, the clinical trial is a randomized, double-blind, placebo-controlled Phase I/II clinical study. On April 27, the new crown inactivated vaccine was approved for clinical trials, and the Phase I/II clinical trials were started simultaneously in Shangqiu County, Henan Province.
“As of now, 1120 subjects in Phase I/II clinical studies have all completed 2 doses of vaccination.”
According to China Biotech, relevant experts said that after vaccination, it has shown good safety and immunogenicity. All subjects in the vaccination group produced high-titer antibodies. Reference to previous similar products, combined with existing human data, initially suggests that the new crown vaccine developed this time is safe and effective.
In the research and development of new crown vaccines, China Biotech has launched a “double insurance” model. Its Wuhan Institute of Biological Products obtained the first clinical trial approval for the new crown inactivated vaccine in the world on April 12, and related clinical trials were started simultaneously; its subsidiary Beijing Biological Products Research On April 27, the new crown inactivated vaccine was again approved for clinical trials.
On June 16, the Phase I/II clinical trial of the new coronavirus inactivated vaccine developed by Sinopharm Wuhan Institute of Biological Products was unblinded. The unblinded results showed that the safety after vaccination was good, and there was no serious adverse reaction. Different procedures and different doses After vaccination, all vaccinated persons in the vaccine group produced high-titer antibodies.
Data show that China National Biotech holds 100% equity of Beijing Institute of Biological Products Co., Ltd. and Wuhan Institute of Biological Products Co., Ltd.
In 2 months, the world’s first inactivated vaccine production workshop for the new crown was built, with an annual output of 120 million doses
It is worth mentioning that the Beijing Institute of Biological Products has built the country’s first and only high-grade biosafety production facility. After it is put into use, the new crown vaccine production capacity will reach 120 million doses per year. This is currently the world’s largest new crown inactivation. Vaccine production workshop.
According to the news announced by China National Biotech on May 29, with the strong support of the Beijing Municipal Government, the Beijing Institute of Biological Products completed the construction of the workshop on April 15 in only 2 months. Preliminary assessment on site by experts, construction standards and quality level meet the requirements of biosafety protection.
According to China Biotech, the establishment of the new crown inactivated vaccine production workshop has filled the biosafety gap in the vaccine field for the prevention and control of major emerging infectious diseases in China, and is of great significance to the development and production of drugs and vaccines for the new crown pneumonia epidemic.
In addition, the construction of the Wuhan Institute of Biological Products’ new crown inactivated vaccine workshop is expected to be completed by the end of June or early July. By then, the two research institutes of China Biology will have an annual production capacity of more than 200 million doses to ensure the accessibility of the new crown inactivated vaccine.
The reporter noticed that the construction of the new crown vaccine production workshop of Beijing Kexing Zhongwei has already started. According to the announcement issued by the Propaganda Department of Beijing Haidian District in April, the Beijing Municipal Party Committee and Municipal Government immediately coordinated a plant with a construction area of 70,000 square meters in the biomedical base in Daxing District and provided it to Kexing Zhongwei for the production of new crown vaccines. workshop.
In May of this year, Yin Weidong, chairman of Kexing Holdings, publicly stated that the new crown vaccine production workshop is under construction 24 hours a day and is expected to be put into trial production in July.
On June 14, Kexing Holdings announced that its Phase I/II clinical study of the new coronavirus inactivated vaccine developed by Beijing Kexing Zhongwei has been unblinded. The preliminary results show that the vaccine has good safety and immunogen. Sex.
Beijing News Shell Finance reporter Li Yunqi editor Xu Chao proofreading Liu Jun